These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 20605106)

  • 21. Effects of rotigotine transdermal patch in patients with Parkinson's disease presenting with non-motor symptoms - results of a double-blind, randomized, placebo-controlled trial.
    Antonini A; Bauer L; Dohin E; Oertel WH; Rascol O; Reichmann H; Schmid M; Singh P; Tolosa E; Chaudhuri KR
    Eur J Neurol; 2015 Oct; 22(10):1400-7. PubMed ID: 26095948
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Local effects of transdermal treatment with rotigotine].
    Bermejo PE; Zea MA; Alba-Alcántara L; Ruiz-Huete C
    Rev Neurol; 2013 Apr; 56(7):359-62. PubMed ID: 23520004
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Rotigotine transdermal patch enables rapid titration to effective doses in advanced-stage idiopathic Parkinson disease: subanalysis of a parallel group, open-label, dose-escalation study.
    Babic T; Boothmann B; Polivka J; Rektor I; Boroojerdi B; Häck HJ; Randerath O
    Clin Neuropharmacol; 2006; 29(4):238-42. PubMed ID: 16855426
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Drug safety evaluation of rotigotine.
    Sprenger FS; Seppi K; Poewe W
    Expert Opin Drug Saf; 2012 May; 11(3):503-12. PubMed ID: 22468676
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A Randomized Controlled Exploratory Pilot Study to Evaluate the Effect of Rotigotine Transdermal Patch on Parkinson's Disease-Associated Chronic Pain.
    Rascol O; Zesiewicz T; Chaudhuri KR; Asgharnejad M; Surmann E; Dohin E; Nilius S; Bauer L
    J Clin Pharmacol; 2016 Jul; 56(7):852-61. PubMed ID: 26626320
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Transdermal rotigotine in early stage Parkinson's disease: a randomized, double-blind, placebo-controlled trial.
    Mizuno Y; Nomoto M; Kondo T; Hasegawa K; Murata M; Takeuchi M; Ikeda J; Tomida T; Hattori N;
    Mov Disord; 2013 Sep; 28(10):1447-50. PubMed ID: 23801585
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Long-term safety and tolerability of rotigotine transdermal system in patients with early-stage idiopathic Parkinson's disease: a prospective, open-label extension study.
    Elmer LW; Surmann E; Boroojerdi B; Jankovic J
    Parkinsonism Relat Disord; 2012 Jun; 18(5):488-93. PubMed ID: 22326237
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Safety, tolerability, and efficacy of continuous transdermal dopaminergic stimulation with rotigotine patch in early-stage idiopathic Parkinson disease.
    Güldenpfennig WM; Poole KH; Sommerville KW; Boroojerdi B
    Clin Neuropharmacol; 2005; 28(3):106-10. PubMed ID: 15965307
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Rotigotine: transdermal dopamine agonist treatment of Parkinson's disease and restless legs syndrome.
    Splinter MY
    Ann Pharmacother; 2007 Feb; 41(2):285-95. PubMed ID: 17213296
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Transdermal rotigotine: a clinically innovative dopamine-receptor agonist for the management of Parkinson's disease.
    Chen JJ; Swope DM; Dashtipour K; Lyons KE
    Pharmacotherapy; 2009 Dec; 29(12):1452-67. PubMed ID: 19947805
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Patients' perception of Parkinson's disease-associated pain following initiation of rotigotine: a multicenter non-interventional study.
    Timmermann L; Oehlwein C; Ransmayr G; Fröhlich H; Will E; Schroeder H; Lauterbach T; Bauer L; Kassubek J
    Postgrad Med; 2017 Jan; 129(1):46-54. PubMed ID: 27883297
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Rotigotine transdermal delivery for the treatment of Parkinson's disease.
    Rascol O; Perez-Lloret S
    Expert Opin Pharmacother; 2009 Mar; 10(4):677-91. PubMed ID: 19239399
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Rotigotine transdermal system for the treatment of Parkinson's disease.
    Pham DQ; Nogid A
    Clin Ther; 2008 May; 30(5):813-24. PubMed ID: 18555929
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Rotigotine transdermal patch in the management of Parkinson's disease (PD) and its night-time use for PD-related sleep disorders.
    Antonini A; Bernardi L; Calandrella D; Mancini F; Plebani M
    Funct Neurol; 2010; 25(1):21-5. PubMed ID: 20626993
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Non-ergot dopamine agonist rotigotine as a promising therapeutic tool in atypical parkinsonism syndromes: a 24 months pilot observational open-label study.
    Moretti DV; Binetti G; Zanetti O; Frisoni GB
    Neuropharmacology; 2014 Oct; 85():284-9. PubMed ID: 24915072
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Rotigotine transdermal patch in Chinese patients with early Parkinson's disease: A randomized, double-blind, placebo-controlled pivotal study.
    Zhang ZX; Shang HF; Hu X; Chen S; Zhao Z; Du X; Surmann E; Bauer L; Asgharnejad M
    Parkinsonism Relat Disord; 2016 Jul; 28():49-55. PubMed ID: 27172830
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effects of long-term treatment with rotigotine transdermal system on dyskinesia in patients with early-stage Parkinson's disease.
    Giladi N; Ghys L; Surmann E; Boroojerdi B; Jankovic J
    Parkinsonism Relat Disord; 2014 Dec; 20(12):1345-51. PubMed ID: 25444083
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pharmacokinetics, safety and tolerability of rotigotine transdermal patch in healthy Japanese and Caucasian subjects.
    Cawello W; Kim SR; Braun M; Elshoff JP; Ikeda J; Funaki T
    Clin Drug Investig; 2014 Feb; 34(2):95-105. PubMed ID: 24178238
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Spotlight on rotigotine transdermal patch in Parkinson's disease.
    Sanford M; Scott LJ
    Drugs Aging; 2011 Dec; 28(12):1015-7. PubMed ID: 22117099
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Rotigotine transdermal patch: a review of its use in the management of Parkinson's disease.
    Baldwin CM; Keating GM
    CNS Drugs; 2007; 21(12):1039-55. PubMed ID: 18020483
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.